苏36
08-26
The key takeaway is that money has not simply waited for Nvidia’s earnings—it has rotated around them. AMD, Nebius and other names rallied on company-specific catalysts, suggesting investors are selectively pricing opportunities rather than making a broad semiconductor bet.

That matters because Nvidia’s results may reset the entire queue. With expectations already extremely high, a simple earnings beat may no longer be enough; investors will likely focus on guidance, AI spending sustainability and whether Nvidia’s financing relationships create additional risk.

In my view, Tuesday’s moves are less a sign of money abandoning Nvidia than a sign that investors are reducing event risk while searching for the next layer of AI beneficiaries. Once Nvidia reports, capital could quickly rotate again depending on whether the numbers exceed an already demanding bar. The real question is not who rises before earnings, but who still has a credible growth story after them.

Cancer Vaccine Valued at $9.2B Peak Sales — Can Moderna Hold a 14% Gain?
Moderna +14.36% to $158.83 Tuesday after Wolfe Research moved it from Underperform to Peer Perform — a 14% move on an upgrade to neutral, which shows how empty positioning was — modeling peak sales near $9.2bn for intismeran. Barclays raised its target to $125, still below the current price. The pricing has migrated: the first 176.97% was short covering, this leg prices annual revenue potential. Against it: full data unpublished, peak sales are model assumptions not orders, LTM revenue $2.23bn and down 27.6%. Build on the $9.2bn thesis, rotate to Merck, or wait for the data?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • qwertd
    08-26
    qwertd
    Broadcom and TSMC probably catch the next leg if the guide holds up. I care more about AI capex durability than the beat itself
Leave a comment
1